SQZ Biotechnologies Company (SQZB)

OTCMKTS · Delayed Price · Currency is USD
0.0240
-0.0001 (-0.41%)
At close: Mar 4, 2026
-65.71%
Market Cap 707.79K
Revenue (ttm) 12.12M
Net Income (ttm) -71.64M
Shares Out 29.49M
EPS (ttm) -2.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,450
Average Volume 4,519
Open 0.0240
Previous Close 0.0241
Day's Range 0.0240 - 0.0240
52-Week Range 0.0228 - 0.0528
Beta 0.33
RSI 48.02
Earnings Date n/a

About SQZB

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 53
Stock Exchange OTCMKTS
Ticker Symbol SQZB
Full Company Profile

Financial Performance

In 2022, SQZB's revenue was $21.48 million, a decrease of -20.74% compared to the previous year's $27.10 million. Losses were -$79.46 million, 15.6% more than in 2021.

Financial Statements

News

There is no news available yet.